Metastatic adenocarcinoma of the endometrium treated with 13‐cis‐retinoic acid plus interferon‐α
Metastatic adenocarcinoma of the endometrium treated with 13‐cis‐retinoic acid plus interferon‐α
复制标题
13顺式维A酸联合干扰素治疗子宫内膜转移性腺癌
作者：
A. Kudelka;R. Freedman;C. Edwards;S. Lippman;C. Tornos;I. Krakoff;J. Kavanagh
13-顺式维甲酸加干扰素(IFN)-α的新型生物组合的II期试验已经在皮肤和宫颈的晚期鳞状细胞癌中取得了主要的活性，但在肺或头颈部没有。除了鳞状癌外，对这种组合的研究非常有限。虽然不常见，但不可切除或转移性子宫内膜腺癌实际上是无法治愈的，化疗对这些病例的生存没有影响。本报告描述了我们使用13-顺式维甲酸加IFN-α治疗一例顺铂和激素抵抗，局部晚期和远处转移的子宫内膜腺癌。在这个预后最差的病例中，生物治疗取得了主要的反应，并持续了4个月。基于该病例的显著活性，我们认为这种有前景的新生物组合的深入机制和临床研究应扩大到包括许多不同部位和组织病理类型的非鳞状肿瘤。
Phase II trials of the novel biologic combination of 13-cis-retinoic acid plus interferon (IFN)-α have achieved major activity in advanced squamous cell carcinomas of the skin and cervix, but not of the lung or head and neck. Very limited study of this combination has occurred in cancers other than those of squamous type. Although uncommon, cases of unresectable or metastatic endometrial adenocarcinoma are virtually incurable, and chemotherapy has had no impact on survival in these cases. This report describes our use of 13-cis-retinoic acid plus IFN-α to treat a case of cisplatin- and hormone-resistant, locally advanced and distantly metastatic adenocarcinoma of the endometrium. In this worst-prognosis case, the biologic therapy achieved a major response, which persisted for 4 months. Based on the dramatic activity in this case, we believe that depthful mechanistic and clinical study of this promising new biologic combination should be expanded to include non-squamous tumors of many different sites and histopathologic types.